+Follow
57dbeb80
No personal profile
5
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
57dbeb80
2022-01-11
Nice
Illumina shares jumped over 6% in morning trading
57dbeb80
2022-01-07
Nice
58 Biggest Movers from Yesterday
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":4104478370114780,"uuid":"4104478370114780","gmtCreate":1641437794400,"gmtModify":1641437794400,"name":"57dbeb80","pinyin":"57dbeb80","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":1,"fanSize":0,"headSize":5,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.06","exceedPercentage":"60.94%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.09","exceedPercentage":"60.77%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9002389794,"gmtCreate":1641915365745,"gmtModify":1676533661620,"author":{"id":"4104478370114780","authorId":"4104478370114780","authorIdStr":"4104478370114780","name":"57dbeb80","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104478370114780"},"themes":[],"htmlText":"Nice ","listText":"Nice ","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002389794","repostId":"2202783004","repostType":4,"repost":{"id":"2202783004","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641912541,"share":"https://ttm.financial/m/news/2202783004?lang=&edition=fundamental","pubTime":"2022-01-11 22:49","market":"hk","language":"en","title":"Illumina shares jumped over 6% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2202783004","media":"Tiger Newspress","summary":"At the J.P.","content":"<html><head></head><body><p>Illumina shares jumped 6% in morning trading. Illumina issued a 2022 revenue outlook that exceeded consensus analysts’ estimates, noting strong demand for its gene sequencing treatments as well as new partnerships with four health care companies.</p><p><img src=\"https://static.tigerbbs.com/9d5a9082aef8a5353dff42035a5ef141\" tg-width=\"1019\" tg-height=\"633\" referrerpolicy=\"no-referrer\"/></p><p>At the J.P. Morgan Healthcare Conference, <b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Inc </b>said it expects about $4.517 billion, +39% Y/Y in 2021 revenue after the company logged the highest number of international product shipments in its history, said CEO Francis deSouza during a presentation<b>. </b></p><ul><li>Illumina projected sales of $5.15 billion - $5.24 billion for FY22, as global demand continues to rise.</li><li><b>New Products and Partnerships:</b> The Company unveiled plans for developing long-read DNA sequencing capabilities for its current installed base of about 20,000 machines.</li><li>Infinity, the updated library prep system, will aim to deliver contiguous data up to 10 kilobase pairs in length to help sequence the remaining 5% of the genome.</li><li>DeSouza also raised the curtain on a new Illumina project dubbed Chemistry X, which he described as a ground-up redevelopment of the company's reagents, dyes, and polymerases.</li><li>The ultimate goal is to sequence a human genome for less than $100 while being faster and more accurate.</li><li>Illumina has already begun setting up a new large-scale manufacturing facility, deSouza said, and has slated Chemistry X to serve as the foundation for all of the company's future platforms.</li><li><b>Partnerships:</b> Illumina will work to develop multiple companion diagnostic tests for <b>Boehringer Ingelheim's c</b>ancer therapy pipeline linked to a planned clinical, comprehensive tumor sequencing test built off of its research-use-only TruSight Oncology 500 assay.</li><li>At the same time, it will work with <b>Agendia</b> <b>Inc </b>to make sure its breast cancer tests are compatible with Illumina sequencers, allowing for diagnostic screening to be performed in-house at any equipped hospital lab.</li><li><b>Price Action:</b> ILMN shares are up 4.89% at $380 during the premarket session on the last check Tuesday.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina shares jumped over 6% in morning trading </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina shares jumped over 6% in morning trading \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-11 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Illumina shares jumped 6% in morning trading. Illumina issued a 2022 revenue outlook that exceeded consensus analysts’ estimates, noting strong demand for its gene sequencing treatments as well as new partnerships with four health care companies.</p><p><img src=\"https://static.tigerbbs.com/9d5a9082aef8a5353dff42035a5ef141\" tg-width=\"1019\" tg-height=\"633\" referrerpolicy=\"no-referrer\"/></p><p>At the J.P. Morgan Healthcare Conference, <b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Inc </b>said it expects about $4.517 billion, +39% Y/Y in 2021 revenue after the company logged the highest number of international product shipments in its history, said CEO Francis deSouza during a presentation<b>. </b></p><ul><li>Illumina projected sales of $5.15 billion - $5.24 billion for FY22, as global demand continues to rise.</li><li><b>New Products and Partnerships:</b> The Company unveiled plans for developing long-read DNA sequencing capabilities for its current installed base of about 20,000 machines.</li><li>Infinity, the updated library prep system, will aim to deliver contiguous data up to 10 kilobase pairs in length to help sequence the remaining 5% of the genome.</li><li>DeSouza also raised the curtain on a new Illumina project dubbed Chemistry X, which he described as a ground-up redevelopment of the company's reagents, dyes, and polymerases.</li><li>The ultimate goal is to sequence a human genome for less than $100 while being faster and more accurate.</li><li>Illumina has already begun setting up a new large-scale manufacturing facility, deSouza said, and has slated Chemistry X to serve as the foundation for all of the company's future platforms.</li><li><b>Partnerships:</b> Illumina will work to develop multiple companion diagnostic tests for <b>Boehringer Ingelheim's c</b>ancer therapy pipeline linked to a planned clinical, comprehensive tumor sequencing test built off of its research-use-only TruSight Oncology 500 assay.</li><li>At the same time, it will work with <b>Agendia</b> <b>Inc </b>to make sure its breast cancer tests are compatible with Illumina sequencers, allowing for diagnostic screening to be performed in-house at any equipped hospital lab.</li><li><b>Price Action:</b> ILMN shares are up 4.89% at $380 during the premarket session on the last check Tuesday.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4121":"生命科学工具和服务","BK4534":"瑞士信贷持仓","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2202783004","content_text":"Illumina shares jumped 6% in morning trading. Illumina issued a 2022 revenue outlook that exceeded consensus analysts’ estimates, noting strong demand for its gene sequencing treatments as well as new partnerships with four health care companies.At the J.P. Morgan Healthcare Conference, Illumina Inc said it expects about $4.517 billion, +39% Y/Y in 2021 revenue after the company logged the highest number of international product shipments in its history, said CEO Francis deSouza during a presentation. Illumina projected sales of $5.15 billion - $5.24 billion for FY22, as global demand continues to rise.New Products and Partnerships: The Company unveiled plans for developing long-read DNA sequencing capabilities for its current installed base of about 20,000 machines.Infinity, the updated library prep system, will aim to deliver contiguous data up to 10 kilobase pairs in length to help sequence the remaining 5% of the genome.DeSouza also raised the curtain on a new Illumina project dubbed Chemistry X, which he described as a ground-up redevelopment of the company's reagents, dyes, and polymerases.The ultimate goal is to sequence a human genome for less than $100 while being faster and more accurate.Illumina has already begun setting up a new large-scale manufacturing facility, deSouza said, and has slated Chemistry X to serve as the foundation for all of the company's future platforms.Partnerships: Illumina will work to develop multiple companion diagnostic tests for Boehringer Ingelheim's cancer therapy pipeline linked to a planned clinical, comprehensive tumor sequencing test built off of its research-use-only TruSight Oncology 500 assay.At the same time, it will work with Agendia Inc to make sure its breast cancer tests are compatible with Illumina sequencers, allowing for diagnostic screening to be performed in-house at any equipped hospital lab.Price Action: ILMN shares are up 4.89% at $380 during the premarket session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006037478,"gmtCreate":1641549750024,"gmtModify":1676533628117,"author":{"id":"4104478370114780","authorId":"4104478370114780","authorIdStr":"4104478370114780","name":"57dbeb80","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104478370114780"},"themes":[],"htmlText":"Nice ","listText":"Nice ","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006037478","repostId":"1124727053","repostType":4,"repost":{"id":"1124727053","pubTimestamp":1641549106,"share":"https://ttm.financial/m/news/1124727053?lang=&edition=fundamental","pubTime":"2022-01-07 17:51","market":"us","language":"en","title":"58 Biggest Movers from Yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=1124727053","media":"Benzinga","summary":"GainersEargo, Inc. shares climbed 59.7% to close at $7.28 on Thurs after the company announced the D","content":"<html><head></head><body><p>Gainers</p><ul><li><b>Eargo, Inc.</b> shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe is no long active.</li><li><b>Alterity Therapeutics Limited</b> gained 33.8% to settle at $1.11 after the company announced it was granted a new US patent for "Compounds for and Methods of Treating Diseases."</li><li><b>China Natural Resources, Inc.</b> surged 27.8% to close at $0.86.</li><li><b>Vocera Communications, Inc.</b> climbed 26.6% to close at $79.17 after Stryker announced a definitive agreement to acquire the company.</li><li><b>Nanobiotix S.A.</b> rose 22.2% to close at $9.85. NANOBIOTIX said first patient was enrolled in NANORAY-312 global Phase III registrational study of NBTXR3 in head and neck cancer.</li><li><b>Kaival Brands Innovations Group, Inc.</b> gained 21.4% to close at $0.7633 after declining more than 11% on Wednesday.</li><li><b>IMAC Holdings, Inc.</b> surged 21.1% to settle at $1.38.</li><li><b>AgeX Therapeutics, Inc.</b> rose 20.1% to close at $1.20.</li><li><b>Phunware, Inc.</b> jumped 19.9% to settle at $3.07.</li><li><b>Digital World Acquisition Corp.</b> rose 19.7% to settle at $60.27.</li><li><b>Ensysce Biosciences, Inc.</b> gained 18.2% to close at $4.75.</li><li><b>Magenta Therapeutics, Inc.</b> shares jumped 16.1% to close at $5.18. Goldman Sachs upgraded Magenta Therapeutics from Neutral to Buy and raised the price target from $7 to $8.</li><li><b>Beyond Meat, Inc.</b> surged 14.7% to settle at $67.06. The company recently announced the debut of Beyond Fried Chicken with KFC nationwide.</li><li><b>VIA optronics AG</b> gained 14.6% to close at $8.87.</li><li><b>Richardson Electronics, Ltd.</b> rose 13.6% to close at $14.36 after the company reported a year-over-year rise in Q2 results.</li><li><b>East Stone Acquisition Corporation</b> jumped 13.2% to settle at $14.77.</li><li><b>Allbirds, Inc.</b> gained 12.2% to close at $15.23 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and lowered its price target from $23 to $17.</li><li><b>Consumer Portfolio Services, Inc.</b> rose 12.1% to close at $11.97.</li><li><b>Resources Connection, Inc.</b> jumped 8.4% to close at $19.72 after reporting better-than-expected Q2 results.</li><li><b>Bed Bath & Beyond Inc.</b> gained 8% to close at $14.43 after the company reported Q3 earnings results and issued guidance.</li><li><b>Lamb Weston Holdings, Inc.</b> gained 7.5% to settle at $67.82 after the company announced better-than-expected Q2 EPS and sales results.</li><li><b>SomaLogic, Inc.</b> rose 4.1% to close at $10.76 after the company announced an exclusive partnership with Illumina to develop sequencing-based proteomic solutions.</li></ul><p><b>Losers</b></p><ul><li><b>Dogness (International) Corporation</b> shares fell 61.9% to close at $3.33.</li><li><b>Aligos Therapeutics, Inc.</b> shares dipped 56.7% to settle at $4.59 on Thursday after the company announced that it has halted further development of its STOPS drug candidate, ALG-010133.</li><li><b>Berkeley Lights, Inc.</b> fell 39.3% to close at $9.88 after the company issued weak sales forecast for FY21. The company said it sees FY21 sales of $84 million to $84.5 million, versus analysts’ estimates of $90.9 million and also projects FY22 sales growth of 30% year over year. The company’s CEO Eric D. Hobbs will transition to president of Antibody Therapeutics Line.</li><li><b>OneSmart International Education Group Limited</b> fell 31.3% to close at $0.2749.</li><li><b>Avalo Therapeutics, Inc.</b> fell 31.3% to close at $1.21 after the company reported Phase 1b results for AVTX-002 in moderate to severe Crohn's disease patients and presented additional program updates at the 2022 investor event.</li><li><b>Sutro Biopharma, Inc.</b> tumbled 27.9% to settle at $10.51. Sutro Biopharma announced updated data from the Phase 1 study of STRO-002, an antibody-drug conjugate, for patients with advanced ovarian cancer, which showed that as of the Nov. 8 cut-off date, seven patients had achieved partial responses, five patients had unconfirmed partial responses and the overall response rate was 33% in all evaluable patients.</li><li><b>Olink Holding AB</b> dropped 27.8% to close at $11.33.</li><li><b>Curis, Inc.</b> fell 27.6% to settle at $3.4950 after the company reported updated data with additional encouraging clinical activity in Phase 1/2 study of CA-4948 monotherapy in targeted patients with relapsed or refractory AML and MDS.</li><li><b>CNS Pharmaceuticals, Inc.</b> shares fell 27.6% to close at $0.76 after the company reported a $11.5 million private placement priced at-the-market under Nasdaq rules.</li><li><b>Reliance Global Group, Inc</b> dipped 24.2% to settle at $6.75.</li><li><b>Applied UV, Inc.</b> fell 19.9% to close at $2.37 after declining around 12% on Wednesday.</li><li><b>Humana Inc.</b> dipped 19.4% to settle at $367.53 after the company reaffirmed its FY21 EPS guidance below analyst estimates.</li><li><b>Heliogen, Inc.</b> fell 19.3% to close at $7.88.</li><li><b>Immix Biopharma, Inc.</b> dropped 18.7% to settle at $5.49. The company recently announced the FDA granted Rare Pediatric Disease designation for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma.</li><li><b>Embark Technology, Inc.</b> declined 16.8% to settle at $6.81 after The Bear Cave issued a short report on the company.</li><li><b>PMV Pharmaceuticals, Inc.</b> fell 16.3% to close at $19.04.</li><li><b>Advanced Human Imaging Limited</b> fell 16.2% to close at $4.03.</li><li><b>Greenbrook TMS Inc.</b> dropped 16.2% to settle at $3.20.</li><li><b>Zhangmen Education Inc.</b> fell 15.9% to close at $2.38.</li><li><b>NLS Pharmaceutics AG</b> dipped 15.8% to settle at $1.28. The company recently announced the USPTO granted the company U.S. Patent No. 11207271, entitled A Mazindol Ir/Sr Multilayer Tablet And Its Use For The Treatment Of Attention Deficit/Hyperactivity Disorder.</li><li><b>Jowell Global Ltd.</b> fell 15.8% to close at $5.11.</li><li><b>Longeveron Inc.</b> declined 15.7% to settle at $10.00. Longeveron recently announced initiation of the Phase 2a clinical trial of lomecel-B for the treatment of Alzheimer's Disease.</li><li><b>Stran & Company, Inc.</b> fell 15.4% to close at $4.95. Stran & Company announced a multi-year contract with a 'large national healthcare company.'</li><li><b>Nuvalent, Inc.</b> declined 15.4% to close at $14.77.</li><li><b>uCloudlink Group Inc.</b> dipped 15.1% to settle at $2.41.</li><li><b>Marpai, Inc.</b> fell 14.4% to close at $3.64.</li><li><b>Schnitzer Steel Industries, Inc.</b> shares fell 13.9% to settle at $46.10 after the company reported worse-than-expected Q1 EPS and sales results.</li><li><b>ATA Creativity Global</b> declined 13.9% to settle at $1.98 after dropping around 10% on Wednesday.</li><li><b>Vivint Smart Home, Inc.</b> declined 12.5% to close at $7.66. RBC Capital downgraded Vivint Smart Home from Outperform to Sector Perform and announced $11 price target.</li><li><b>GoHealth, Inc.</b> dropped 12.3% to settle at $2.86.</li><li><b>MicroVision, Inc.</b> shares fell 9.3% to close at $4.48 after dropping more than 12% on Wednesday.</li><li><b>REE Automotive Ltd.</b> dropped 9% to close at $5.84. REE Automotive named David Goldberg as Chief Financial Officer.</li><li><b>Ebang International Holdings Inc.</b> shares fell 8.8% to close at $1.04 after gaining around 10% on Wednesday.</li><li><b>Data Storage Corporation</b> shares fell 8.2% to settle at $3.79. Data Storage shares climbed more than 33% on Wednesday after the company announced a multi-million dollar contract with a professional sports team.</li><li><b>Hoth Therapeutics, Inc.</b> shares fell 7.8% to close at $1.07. Hoth Therapeutics recently announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ.</li><li><b>Connect Biopharma Holdings Limited</b> fell 7% to close at $4.65. Connect Biopharma recently reported detailed dataset from global Phase 2b trial of CBP-201 in adult patients with moderate-to-severe atopic dermatitis.</li></ul></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>58 Biggest Movers from Yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n58 Biggest Movers from Yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 17:51 GMT+8 <a href=https://www.benzinga.com/news/22/01/24943837/58-biggest-movers-from-yesterday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GainersEargo, Inc. shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe is no long active....</p>\n\n<a href=\"https://www.benzinga.com/news/22/01/24943837/58-biggest-movers-from-yesterday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","BBBY":"3B家居","PHUN":"Phunware, Inc."},"source_url":"https://www.benzinga.com/news/22/01/24943837/58-biggest-movers-from-yesterday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124727053","content_text":"GainersEargo, Inc. shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe is no long active.Alterity Therapeutics Limited gained 33.8% to settle at $1.11 after the company announced it was granted a new US patent for \"Compounds for and Methods of Treating Diseases.\"China Natural Resources, Inc. surged 27.8% to close at $0.86.Vocera Communications, Inc. climbed 26.6% to close at $79.17 after Stryker announced a definitive agreement to acquire the company.Nanobiotix S.A. rose 22.2% to close at $9.85. NANOBIOTIX said first patient was enrolled in NANORAY-312 global Phase III registrational study of NBTXR3 in head and neck cancer.Kaival Brands Innovations Group, Inc. gained 21.4% to close at $0.7633 after declining more than 11% on Wednesday.IMAC Holdings, Inc. surged 21.1% to settle at $1.38.AgeX Therapeutics, Inc. rose 20.1% to close at $1.20.Phunware, Inc. jumped 19.9% to settle at $3.07.Digital World Acquisition Corp. rose 19.7% to settle at $60.27.Ensysce Biosciences, Inc. gained 18.2% to close at $4.75.Magenta Therapeutics, Inc. shares jumped 16.1% to close at $5.18. Goldman Sachs upgraded Magenta Therapeutics from Neutral to Buy and raised the price target from $7 to $8.Beyond Meat, Inc. surged 14.7% to settle at $67.06. The company recently announced the debut of Beyond Fried Chicken with KFC nationwide.VIA optronics AG gained 14.6% to close at $8.87.Richardson Electronics, Ltd. rose 13.6% to close at $14.36 after the company reported a year-over-year rise in Q2 results.East Stone Acquisition Corporation jumped 13.2% to settle at $14.77.Allbirds, Inc. gained 12.2% to close at $15.23 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and lowered its price target from $23 to $17.Consumer Portfolio Services, Inc. rose 12.1% to close at $11.97.Resources Connection, Inc. jumped 8.4% to close at $19.72 after reporting better-than-expected Q2 results.Bed Bath & Beyond Inc. gained 8% to close at $14.43 after the company reported Q3 earnings results and issued guidance.Lamb Weston Holdings, Inc. gained 7.5% to settle at $67.82 after the company announced better-than-expected Q2 EPS and sales results.SomaLogic, Inc. rose 4.1% to close at $10.76 after the company announced an exclusive partnership with Illumina to develop sequencing-based proteomic solutions.LosersDogness (International) Corporation shares fell 61.9% to close at $3.33.Aligos Therapeutics, Inc. shares dipped 56.7% to settle at $4.59 on Thursday after the company announced that it has halted further development of its STOPS drug candidate, ALG-010133.Berkeley Lights, Inc. fell 39.3% to close at $9.88 after the company issued weak sales forecast for FY21. The company said it sees FY21 sales of $84 million to $84.5 million, versus analysts’ estimates of $90.9 million and also projects FY22 sales growth of 30% year over year. The company’s CEO Eric D. Hobbs will transition to president of Antibody Therapeutics Line.OneSmart International Education Group Limited fell 31.3% to close at $0.2749.Avalo Therapeutics, Inc. fell 31.3% to close at $1.21 after the company reported Phase 1b results for AVTX-002 in moderate to severe Crohn's disease patients and presented additional program updates at the 2022 investor event.Sutro Biopharma, Inc. tumbled 27.9% to settle at $10.51. Sutro Biopharma announced updated data from the Phase 1 study of STRO-002, an antibody-drug conjugate, for patients with advanced ovarian cancer, which showed that as of the Nov. 8 cut-off date, seven patients had achieved partial responses, five patients had unconfirmed partial responses and the overall response rate was 33% in all evaluable patients.Olink Holding AB dropped 27.8% to close at $11.33.Curis, Inc. fell 27.6% to settle at $3.4950 after the company reported updated data with additional encouraging clinical activity in Phase 1/2 study of CA-4948 monotherapy in targeted patients with relapsed or refractory AML and MDS.CNS Pharmaceuticals, Inc. shares fell 27.6% to close at $0.76 after the company reported a $11.5 million private placement priced at-the-market under Nasdaq rules.Reliance Global Group, Inc dipped 24.2% to settle at $6.75.Applied UV, Inc. fell 19.9% to close at $2.37 after declining around 12% on Wednesday.Humana Inc. dipped 19.4% to settle at $367.53 after the company reaffirmed its FY21 EPS guidance below analyst estimates.Heliogen, Inc. fell 19.3% to close at $7.88.Immix Biopharma, Inc. dropped 18.7% to settle at $5.49. The company recently announced the FDA granted Rare Pediatric Disease designation for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma.Embark Technology, Inc. declined 16.8% to settle at $6.81 after The Bear Cave issued a short report on the company.PMV Pharmaceuticals, Inc. fell 16.3% to close at $19.04.Advanced Human Imaging Limited fell 16.2% to close at $4.03.Greenbrook TMS Inc. dropped 16.2% to settle at $3.20.Zhangmen Education Inc. fell 15.9% to close at $2.38.NLS Pharmaceutics AG dipped 15.8% to settle at $1.28. The company recently announced the USPTO granted the company U.S. Patent No. 11207271, entitled A Mazindol Ir/Sr Multilayer Tablet And Its Use For The Treatment Of Attention Deficit/Hyperactivity Disorder.Jowell Global Ltd. fell 15.8% to close at $5.11.Longeveron Inc. declined 15.7% to settle at $10.00. Longeveron recently announced initiation of the Phase 2a clinical trial of lomecel-B for the treatment of Alzheimer's Disease.Stran & Company, Inc. fell 15.4% to close at $4.95. Stran & Company announced a multi-year contract with a 'large national healthcare company.'Nuvalent, Inc. declined 15.4% to close at $14.77.uCloudlink Group Inc. dipped 15.1% to settle at $2.41.Marpai, Inc. fell 14.4% to close at $3.64.Schnitzer Steel Industries, Inc. shares fell 13.9% to settle at $46.10 after the company reported worse-than-expected Q1 EPS and sales results.ATA Creativity Global declined 13.9% to settle at $1.98 after dropping around 10% on Wednesday.Vivint Smart Home, Inc. declined 12.5% to close at $7.66. RBC Capital downgraded Vivint Smart Home from Outperform to Sector Perform and announced $11 price target.GoHealth, Inc. dropped 12.3% to settle at $2.86.MicroVision, Inc. shares fell 9.3% to close at $4.48 after dropping more than 12% on Wednesday.REE Automotive Ltd. dropped 9% to close at $5.84. REE Automotive named David Goldberg as Chief Financial Officer.Ebang International Holdings Inc. shares fell 8.8% to close at $1.04 after gaining around 10% on Wednesday.Data Storage Corporation shares fell 8.2% to settle at $3.79. Data Storage shares climbed more than 33% on Wednesday after the company announced a multi-million dollar contract with a professional sports team.Hoth Therapeutics, Inc. shares fell 7.8% to close at $1.07. Hoth Therapeutics recently announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ.Connect Biopharma Holdings Limited fell 7% to close at $4.65. Connect Biopharma recently reported detailed dataset from global Phase 2b trial of CBP-201 in adult patients with moderate-to-severe atopic dermatitis.","news_type":1},"isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9002389794,"gmtCreate":1641915365745,"gmtModify":1676533661620,"author":{"id":"4104478370114780","authorId":"4104478370114780","authorIdStr":"4104478370114780","name":"57dbeb80","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104478370114780"},"themes":[],"htmlText":"Nice ","listText":"Nice ","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002389794","repostId":"2202783004","repostType":4,"repost":{"id":"2202783004","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641912541,"share":"https://ttm.financial/m/news/2202783004?lang=&edition=fundamental","pubTime":"2022-01-11 22:49","market":"hk","language":"en","title":"Illumina shares jumped over 6% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2202783004","media":"Tiger Newspress","summary":"At the J.P.","content":"<html><head></head><body><p>Illumina shares jumped 6% in morning trading. Illumina issued a 2022 revenue outlook that exceeded consensus analysts’ estimates, noting strong demand for its gene sequencing treatments as well as new partnerships with four health care companies.</p><p><img src=\"https://static.tigerbbs.com/9d5a9082aef8a5353dff42035a5ef141\" tg-width=\"1019\" tg-height=\"633\" referrerpolicy=\"no-referrer\"/></p><p>At the J.P. Morgan Healthcare Conference, <b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Inc </b>said it expects about $4.517 billion, +39% Y/Y in 2021 revenue after the company logged the highest number of international product shipments in its history, said CEO Francis deSouza during a presentation<b>. </b></p><ul><li>Illumina projected sales of $5.15 billion - $5.24 billion for FY22, as global demand continues to rise.</li><li><b>New Products and Partnerships:</b> The Company unveiled plans for developing long-read DNA sequencing capabilities for its current installed base of about 20,000 machines.</li><li>Infinity, the updated library prep system, will aim to deliver contiguous data up to 10 kilobase pairs in length to help sequence the remaining 5% of the genome.</li><li>DeSouza also raised the curtain on a new Illumina project dubbed Chemistry X, which he described as a ground-up redevelopment of the company's reagents, dyes, and polymerases.</li><li>The ultimate goal is to sequence a human genome for less than $100 while being faster and more accurate.</li><li>Illumina has already begun setting up a new large-scale manufacturing facility, deSouza said, and has slated Chemistry X to serve as the foundation for all of the company's future platforms.</li><li><b>Partnerships:</b> Illumina will work to develop multiple companion diagnostic tests for <b>Boehringer Ingelheim's c</b>ancer therapy pipeline linked to a planned clinical, comprehensive tumor sequencing test built off of its research-use-only TruSight Oncology 500 assay.</li><li>At the same time, it will work with <b>Agendia</b> <b>Inc </b>to make sure its breast cancer tests are compatible with Illumina sequencers, allowing for diagnostic screening to be performed in-house at any equipped hospital lab.</li><li><b>Price Action:</b> ILMN shares are up 4.89% at $380 during the premarket session on the last check Tuesday.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina shares jumped over 6% in morning trading </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina shares jumped over 6% in morning trading \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-11 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Illumina shares jumped 6% in morning trading. Illumina issued a 2022 revenue outlook that exceeded consensus analysts’ estimates, noting strong demand for its gene sequencing treatments as well as new partnerships with four health care companies.</p><p><img src=\"https://static.tigerbbs.com/9d5a9082aef8a5353dff42035a5ef141\" tg-width=\"1019\" tg-height=\"633\" referrerpolicy=\"no-referrer\"/></p><p>At the J.P. Morgan Healthcare Conference, <b><a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Inc </b>said it expects about $4.517 billion, +39% Y/Y in 2021 revenue after the company logged the highest number of international product shipments in its history, said CEO Francis deSouza during a presentation<b>. </b></p><ul><li>Illumina projected sales of $5.15 billion - $5.24 billion for FY22, as global demand continues to rise.</li><li><b>New Products and Partnerships:</b> The Company unveiled plans for developing long-read DNA sequencing capabilities for its current installed base of about 20,000 machines.</li><li>Infinity, the updated library prep system, will aim to deliver contiguous data up to 10 kilobase pairs in length to help sequence the remaining 5% of the genome.</li><li>DeSouza also raised the curtain on a new Illumina project dubbed Chemistry X, which he described as a ground-up redevelopment of the company's reagents, dyes, and polymerases.</li><li>The ultimate goal is to sequence a human genome for less than $100 while being faster and more accurate.</li><li>Illumina has already begun setting up a new large-scale manufacturing facility, deSouza said, and has slated Chemistry X to serve as the foundation for all of the company's future platforms.</li><li><b>Partnerships:</b> Illumina will work to develop multiple companion diagnostic tests for <b>Boehringer Ingelheim's c</b>ancer therapy pipeline linked to a planned clinical, comprehensive tumor sequencing test built off of its research-use-only TruSight Oncology 500 assay.</li><li>At the same time, it will work with <b>Agendia</b> <b>Inc </b>to make sure its breast cancer tests are compatible with Illumina sequencers, allowing for diagnostic screening to be performed in-house at any equipped hospital lab.</li><li><b>Price Action:</b> ILMN shares are up 4.89% at $380 during the premarket session on the last check Tuesday.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4121":"生命科学工具和服务","BK4534":"瑞士信贷持仓","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2202783004","content_text":"Illumina shares jumped 6% in morning trading. Illumina issued a 2022 revenue outlook that exceeded consensus analysts’ estimates, noting strong demand for its gene sequencing treatments as well as new partnerships with four health care companies.At the J.P. Morgan Healthcare Conference, Illumina Inc said it expects about $4.517 billion, +39% Y/Y in 2021 revenue after the company logged the highest number of international product shipments in its history, said CEO Francis deSouza during a presentation. Illumina projected sales of $5.15 billion - $5.24 billion for FY22, as global demand continues to rise.New Products and Partnerships: The Company unveiled plans for developing long-read DNA sequencing capabilities for its current installed base of about 20,000 machines.Infinity, the updated library prep system, will aim to deliver contiguous data up to 10 kilobase pairs in length to help sequence the remaining 5% of the genome.DeSouza also raised the curtain on a new Illumina project dubbed Chemistry X, which he described as a ground-up redevelopment of the company's reagents, dyes, and polymerases.The ultimate goal is to sequence a human genome for less than $100 while being faster and more accurate.Illumina has already begun setting up a new large-scale manufacturing facility, deSouza said, and has slated Chemistry X to serve as the foundation for all of the company's future platforms.Partnerships: Illumina will work to develop multiple companion diagnostic tests for Boehringer Ingelheim's cancer therapy pipeline linked to a planned clinical, comprehensive tumor sequencing test built off of its research-use-only TruSight Oncology 500 assay.At the same time, it will work with Agendia Inc to make sure its breast cancer tests are compatible with Illumina sequencers, allowing for diagnostic screening to be performed in-house at any equipped hospital lab.Price Action: ILMN shares are up 4.89% at $380 during the premarket session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006037478,"gmtCreate":1641549750024,"gmtModify":1676533628117,"author":{"id":"4104478370114780","authorId":"4104478370114780","authorIdStr":"4104478370114780","name":"57dbeb80","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104478370114780"},"themes":[],"htmlText":"Nice ","listText":"Nice ","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006037478","repostId":"1124727053","repostType":4,"isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
